- JP-listed companies
- K Pharma,Inc.
- Income statement
K Pharma,Inc.【JP:4896】Income statement
Market cap
¥9.2B
P/E ratio
-13.4x
K Pharma develops treatments for neurological diseases like ALS and Alzheimer's using iPS cell technology and regenerative medicine based on Keio University research.
| 2018/12 | 2019/10 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | - | - | - | - | - | - | 1,000 | - | - |
| Cost of revenue | - | - | - | - | - | - | 90 | - | - |
| Gross profit | - | - | - | - | - | - | 910 | - | - |
| Gross margin (%) | - | - | - | - | - | - | - | - | |
| Operating margin (%) | - | - | - | - | - | - | - | - | |
| Operating expenses | - | - | - | - | 219 | 354 | 544 | 836 | 916 |
| Operating income | - | - | - | - | -219 | -354 | 366 | -836 | -916 |
| Income before tax | -100 | -256 | -256 | -270 | -221 | -359 | 344 | -836 | -920 |
| Pretax margin (%) | - | - | - | - | - | - | 34.4 | - | - |
| Provision for income taxes | - | - | - | - | -0 | 2 | 41 | 2 | 3 |
| Effective tax rate (%) | - | - | - | - | |||||
| Net income | -100 | -256 | -256 | -271 | -229 | -392 | 260 | -846 | -993 |
| Net income margin (%) | - | - | - | - | - | - | - | - | |
| Earnings per share | -16,594.61 | -37,032.98 | -37,032.98 | -38,751.13 | -30.09 | -42.06 | 25.42 | -72.94 | -85.59 |
| Diluted EPS | - | - | - | - | - | - | 23.07 | - | - |
| Dividend payout ratio (%) | - | - | - | - | - | - | - | - | - |
| Dividend per share | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |